

8. Literaturverzeichnis

Agishi T, Kaneko J, Hasuo Y, et al. Double filtration plasmapheresis. 1980. *Ther Apher* 2000;4(1):29-33.

Ali Raza J, Reeves WC & Movahed A. Pharmacological stress agents for evaluation of ischemic heart disease. *Int J Cardiol* 2001;81(2-3):157-167.

Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis* 1994;106(1):9-19.

Al-Saadi N, Nagel E, Gross M, et al. Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. *Circulation* 2000;101(12):1379-1383.

Al-Saadi N, Gross M, Bornstedt A, et al. Comparison of various parameters for determining an index of myocardial perfusion reserve in detecting coronary stenosis with cardiovascular magnetic resonance tomography. *Z Kardiol* 2001;90(11):824-834.

Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Engl J Med* 1995;332(1):488-493.

Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. *J Am Coll Cardiol* 1995;26(5):1235-1241.

Ariyo AA, Thach C & Tracy R. Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. *N Engl J Med* 2003;349(22):2108-2115.

Armstrong VW. Lipoprotein(a). Charakteristik eines besonderen Lipoprotein und dessen mögliche klinische Bedeutung. *Ther Umsch* 1990; 47:475-491.

Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. *Atherosclerosis* 1986;62(3):249-257.

Armstrong VW, Schleef J, Thiery J, et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. *Eur J Clin Invest* 1989;19(3):235-240.

Armstrong VW, Schuff-Werner P, Eisenhauer T, et al. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. *Chem Phys Lipids* 1994;67-68:315-321.

Austin RE, Aldea GS, Coggins DL, Flynn AE, Hoffmann JI. Profound spatial heterogeneity of coronary reserve. Discordance between patterns of resting and maximal myocardial blood flow. *Circ Res* 1990;67(2):319-331.

Bache RJ, McHale PA & Greenfield JC Jr. Transmural myocardial perfusion during restricted coronary inflow in the awake dog. *Am J Physiol* 1977;232(6):H645-651.

Baller D, Gleichmann U, Notohamiprodjo G, et al. Verbesserung der koronaren Vasodilatationskapazität durch medikamentöse Lipidsenkung bei Patienten im Frühstadium der koronaren Atherosklerose mit eingeschränkter Koronarreserve und mäßiggradiger LDL-Hypercholesterinämie. *Z Kardiol* 87 Suppl 2 1998:136-144.

Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall. *Eur Heart J* 1990;11 Suppl E:174-183.

Berg K. A new serum type system in man: the Lp-system. *Acta Pathol Microbiol Scand* 1963;59:369-382.

Bloch F. Nuclear induction. *Phys Rev* 1946;70:460-474.

Bosch Th, Braun N, Fassbinder W, et al. Apheresestandard der Deutschen Arbeitsgemeinschaft für klinische Nephrologie e.V. *Mitteilungen der Deutschen Arbeitsgemeinschaft für Klinische Nephrologie, Band XXXI:103-138, 2002.*

Bosch T, Lennertz A, Schenzle D, et al. Direct adsorption of low-density lipoprotein and lipoprotein (a) from whole blood: Results of the first clinical long-term multicenter study using DALI apheresis. *J Clin Apher* 2002;17(4):161-169.

Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. *JAMA* 1996;276(7):544-548.

Brunner R, Widder RA, Walter P, Borberg H, Oette K. Change in hemorrheological and biochemical parameters following membrane differential filtration. *Int J Artif Organs* 1995; 18(12):794-798.

Canty JM Jr & Klocke FJ. Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve. *Circulation* 1985;71(2):370-377.

Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. *Am J Cardiol* 1998;82(12A):74U-81U; discussion 85U-86U.

Carlson LA, Hamsten A & Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. *J Intern Med* 1989;226(4):271-276.

Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;340(8828):1111-1115.

Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. *J Am Coll Cardiol* 1994;24(2):471-476.

Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002;105(4):539-542.

Chapman CB, Baker O, Reynolds J, et al. Use of biplane cinefluorography for measurement of ventricular volume. *Circulation* 1958;18(6):1105-1117.

Chilian WM. Microvascular pressure and resistances in the left ventricular subepicardium and subendocardium. *Circ Res* 1991;69(3):561-570.

Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. *Clin Chem* 1998;44(11):2301-2306.

Cremer P, Nagel D, Labrot B, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. *Atherosclerosis* 1997;129(2):221-230.

Crnac J, Schmidt MC, Theissen P, Sechtem U. Assessment of myocardial perfusion by magnetic resonance imaging. *Herz* 1997;22(1):16-28. Review.

Dahlen G. The pre-beta lipoprotein phenomenon in relation to serum cholesterol and triglyceride levels, the Lp(a) lipoprotein and coronary heart disease. *Acta Med Scand Suppl* 1974;570:1-45.

Dahlen GH & Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. *Clin Genet* 1997;562(5):272-280.

Daida H, Lee YJ, Kanoh T, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. *Am J Cardiol* 1994;73(15):1037-1040.

Danesh J, Collins R & Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation* 2000;102(10):1082-1085.

Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. *Circulation* 1994;90(2):808-817.

Drexler H & Hornig B. Endothelial dysfunction in human disease. *J Mol Cell Cardiol* 1999;31(1):51-60.

O'Driscoll G, Green D & Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation* 1997;95(5):1126-1131.

Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of Endothelium) Trial. *Circulation* 1999;99(25):3227-3333.

Duvernoy CS, Meyer C, Seifert-Klaus V, et al. Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. *J Am Coll Cardiol* 1999;33(2):463-470.

Earls JP, Ho VB, Foo TK, Castillo E, Flamm SD. Cardiac MRI: recent progress and continued challenges. *J Magn Reson Imaging* 2002;16(2):111-127.

Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. *Proc Natl Acad Sci USA* 1987;84(10):3224-3228.

von Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. *J Am Coll Cardiol* 2001; 37(2):434-439.

Enas EA, Chacko V, Senthilkumar A, Puthumana N, Mohan V. Elevated lipoprotein(a) – a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review. *Dis Mon* 2006;52(1):5-50.

Ernst RR. Nobel Lecture. Nuclear magnetic resonance Fourier transform spectroscopy. *Biosci Rep* 1992;12(3):143-187.

Ernst E & Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med* 1993; 118(12):956-63.

Feigl EO. Coronary physiology. *Physiol Rev* 1983;63(1):1-205.

Feletou M & Vanhoutte PM. Endothelium-dependent hyperpolarisation of canine smooth muscle. *Br J Pharmacol* 1988;93(3):515-524.

Fless GM, ZumMallen ME & Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein(a). *J Biol Chem* 1986;261(19):8712-8718.

Franceschini G, Busnach G, Vaccarino V, Calabresi L, Gianfranceschi G, Sirtori CR. Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. *Atherosclerosis* 1988; 73(2-3):197-202.

Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18(6):499-502.

Furchgott RF & Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;288(5789):373-376.

Gavish D, Azrolan N & Breslow JL. Plasma Lp(a) concentration is inversely correlated with the ratio of Kringel IV/Kringel V encoding domains in the Apo(a) gene. *J Clin Invest* 1989;84(6):2021-2027.

Genest J Jr, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. *Am J Cardiol* 1991;67(13):1039-1045.

Geiss HC, Parhofer KG, Donner MG, Schwandt P. Low Density Lipoprotein apheresis by membrane differential filtration (cascade filtration). *Ther Apher* 1999;3(3):199-202.

Giang TH, Nanz D, Coulden R, et al. Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first european multi-centre experience. *Eur Heart J* 2004;25(18):1657-1665.

Godehardt E, Messner H & Wallstab U. Extracorporeal LDL cholesterol elimination by membrane differential filtration. In: Gotto AM, Mancini M, Richter WO, Schwandt P, editors. *Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease. 4th Int Symp, Munich 1992.* Basel: Karger; 1993.208-212.

Goldberg A, Alagona P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. *Am J Cardiol* 2000; 85(9):1100-1105.

Gonzalez-Gronow M, Edelberg JM & Pizzo SV. Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein(a) compete for the same site. *Biochemistry* 1989;28(6):2374-2377.

Goto M, Flynn AE, Doucette JW, et al. Cardiac contraction affects deep myocardial vessels predominantly. *Am J Physiol* 1991;261(5 Pt 2):H 1417-1429.

Grainger DJ, Kemp PR, Metcalfe JC, et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. *Nat Med* 1995;1(1):74-79.

Helmhold M. Risikofaktor Lp(a): eine Übersicht. In: Helmhold M & Armstrong VW, Hrsg. *Risikofaktor Lp(a).* Weller Verlag, 1995; 1-26.

Herold G und Mitarbeiter. *Innere Medizin. Eine vorlesungsorientierte Darstellung.* Köln, 2003;196-205.

Huang AH & Feigl EO. Adrenergic coronary vasoconstriction helps maintain uniform transmural blood flow distribution during exercise. *Circ Res* 1988;62(2):286-298.

Huber A, Schweyer M, Bauner K, et al. Magnetic resonance imaging for the assessment of myocardial perfusion: value of various semiquantitative perfusion parameters. *Radiologe* 2007;47(4):319-324.

Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reserve. *Circulation* 1998;98(13):1291-1296.

Hummelsheim T, Borberg H, Brunner R, et al. Acute changes of haemorheological parameters by LDL apheresis: specific Immunoabsorption versus Cascade Filtration. *Infusionsther Transfusionsmed* 1995;22(suppl 1):42-44.

Inoue N, Venema RC, Sayegh, et al. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor- β 1. *Arterioscler Thromb Vasc Biol* 1995;15(8):1255-1261.

Ioka T, Tasaki H, Yashiro A, et al. Association between lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. *Circ J* 2002;66(3):267-271.

Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. *Ther Apher* 2001;5(3): 207-211.

Jaeger BR, Bengel FM, Odaka K, et al. Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography. *J Heart Lung Transplant* 2005;24(12):2022-2030. Epub 2005 Sep 15.

Jaeger BR. Wirksamkeit der Lipid-Apherese bei Lp(a)-Hyperlipoproteinämie. 6. Apherese-Therapie-Seminar Berlin, 2006.

Jerosch-Herold M & Wilke N. MR first pass imaging: quantitative assessment of transmural perfusion and collateral flow. *Int J Card Imaging* 1997;13(3):205-218.

Jerosch-Herold M, Wilke N & Stillman AE. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. *Med Phys* 1998;25(1):73-84.

Jones CJ, Kuo L, Davis MJ, Cholian WM. Regulation of coronary blood flow: coordination of heterogeneous control mechanisms in vascular microdomains. *Cardiovasc Res* 1995;29(5):585-596.

Julius U, Siegert G & Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. *Int J Artif Organs* 2000;23(3):199-206.

Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extra-corporal LDL-apheresis methods: Lipidfiltration and HELP. *Int J Artif Organs* 2002;25(12):1180-1188.

Junker R, Heinrich J, Ulbrich H, et al. Relationship between plasma viscosity and the severity of coronary heart disease. *Arterioscler Thromb Vasc Biol* 1998;18(6):870-875.

Kaiser B, Globits S, Mayr H, Mittendorfer M, Salomonowitz E. Myokardiale First Pass-Perfusionsdiagnostik mittels Magnetresonanztomographie. *Journal für Kardiologie* 2003;10(1-2):26-31.

Kane JP & Havel RJ. Disorders of the biogenesis and secretion of lipoprotein containing the B apolipoproteins. In: Scriver CR, Beaudet AL (eds): *The metabolic basis of inherited disease* 6th ed. McGraw-Hill New York 1989.

Kannel WB. An overview of the risk factors for cardiovascular disease. In: *Prevention of Coronary Heart Disease-Practical Management of the Risk Factors*. Philadelphia: WB Saunders Company 1983.

Klingel R, Fassbender T, Fassbender C, Goehlen B. From Membrane Differential Filtration to Lipidfiltration – Technological Progress in LDL-Apheresis. *Ther Apher Dial* 2003;7(3):350-358.

Klingel R, Mausfeld M, Fassbender C, Goehlen B. Lipidfiltration – safe and effective methodology to perform lipid-apheresis. *Transfus Apher Sci* 2004;30(3):245-254.

Klocke FJ. Coronary blood flow in man. *Prog Cardiovasc Dis* 1976;19(2):117-166.

Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apo(a) phenotypes predict coronary artery disease in hemodialysis patients. *J Am Soc Nephrol* 1997;8(12):1889-1898.

Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. *Atherosclerosis* 1981;38(1-2):51-61.

Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. *J Clin Invest* 1989;83(1):137-142.

Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. *Arterioscler Thromb Vasc Biol* 1996;16(6):713-719.

Kramer U, Miller S, Helber U, et al. Variability in the MR tomographic determination of myocardial function and perfusion parameters in health subjects. *Rofo* 2000;172(7):609-614.

Kratzin H, Armstrong VW, Niehaus M, Hilschmann N, Seidel D. Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. *Biol Chem Hoppe Seyler* 1987;368(12):1533-1544.

Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein Lp(a) in man. *J Clin Invest* 1980;65:1483-1490.

Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation* 1999;100(11):1154-1160.

Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein (a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. *Arterioscler Thromb Vasc Biol* 1996;16(12):1568-1572.

Laubenberger T & Laubenberger J. Technik der medizinischen Radiologie. Diagnostik, Strahlentherapie, Strahlenschutz. Für Ärzte, Medizinstudenten und MTRA. Dt. Ärzte-Verlag Köln, 6. Auflage 1994.

Lauterbur PC. Image formation by induced local interactions. Examples employing nuclear magnetic resonance. *Nature* 1973;242:190-191 .

Lerman A & Zeiher AM. Endothelial function: Cardiac events. *Circulation* 2005;111(3):363-368.

Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as a predictor of coronary heart disease: The Prime Study. *Atherosclerosis* 2002;163(2):377-384.

Luley C & Wieland H. Epidemiologie überwiegend genetisch bedingter Dyslipoproteinämien. In: Schwandt P, Richter WO, Parhofer KG, Hrsg. Handbuch der Fettstoffwechselstörungen. Schattauer-Verlag, Stuttgart New York, 2000; 61-71.

Mackinnon LT, Hubinger L & Lepre F. Effects of physical activity and diet on lipoprotein(a). *Med Sci Sports Exerc* 1997;29(11):1429-1436.

Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with Quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. *Circulation* 1996;94:258-265.

Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. *Clin Chem* 2003;49(11):1785-1796.

Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. *Circulation* 1990;82(1):1-7.

Marques-Vidal P, Ferrieres J, Metzger MH, et al. Trends in coronary heart disease morbidity and mortality and acute coronary care and case fatality from 1985-1989 in southern Germany and south-western France. *Eur Heart J* 1997;18(5): 816-821.

Martini RU. Interaktion von nativem und oxidiertem Lp(a) mit menschlichen Mesangialzellen und Matrix. Universität Freiburg, Diss., 2001.

Matic G, Kohlschein P, Wallstab U, et al. Comparison of two filter combinations for low-density lipoprotein apheresis by membrane differential filtration: a prospective crossover controlled clinical study. *Artif Organs* 2002;26(4):371-377.

Mellwig KP, Baller D, Gleichmann U, et al. Improvement of coronary vasodilatation capacity through single LDL apheresis. *Atherosclerosis* 1998;139(1):173-178.

Mellwig KP, Baller D, Schmidt HK, et al. Myokardiale Perfusion unter H.E.L.P.-Apherese, Objektivierung durch PET. *Z Kardiol* 2003;92:Suppl 3, III/30-III/37.

Messroghli DR, Bainbridge GJ, Alfakih K, et al. Assessment of regional left ventricular function: accuracy and reproducibility of positioning standard short-axis sections in cardiac MR imaging. *Radiology* 2005;235(1):229-236.

Moncada S & Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med* 1993;329(27):2002-2012.

Moncada S, Palmer RMJ & Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol Rev* 1991; 43(2):109-142.

Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. *J Clin Invest* 1996;98(10):2414-2424.

- Mostaza JM, Gomez MV, Gallardo F, et al.** Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. *J Am Coll Cardiol* 2000;35(1):76-82.
- Muehling OM, Jerosch-Herold M, Näbauer M, Wilke N.** Assessment of ischemic heart disease using magnetic resonance first-pass perfusion imaging. *Herz* 2003;28(2):82-89.
- Muehling OM, Wilke NM, Panse P, et al.** Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. *J Am Coll Cardiol* 2003;42(6):1054-1060.
- Muehling OM, Jerosch-Herold M, Panse P, et al.** Regional heterogeneity of myocardial perfusion in healthy human myocardium: assessment with magnetic resonance perfusion imaging. *J Cardiovasc Magn Reson* 2004;6(2):499-507.
- Nixdorff U, Mohr-Kahaly S, Wagner S, Meyer J.** Klinischer Stellenwert der Stressechokardiographie. *Dt Ärztebl* 1997;94:A-1723-1728 [Heft 25].
- Palmer RM, Ashton DS & Moncada S.** Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature* 1988;333(6174):664-666.
- Palmer RM, Ferrige AG, Moncada S.** Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature* 1987;327(6122):524-526.
- Panting JR, Gatehouse PD, Yang GZ, et al.** Abnormal subendocardial perfusion in Cardiac syndrome X detected by cardiovascular magnetic resonance imaging. *N Engl J Med* 2002;346(25):1948-1953.
- Parhofer KG, Geiss HC & Schwandt P.** Efficacy of different low-density lipoprotein apheresis methods. *Ther Apher* 2000;4(5):382-385.
- Pennell DJ, Sechtem UP, Higgins CB, et al.** Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. *Eur Heart J* 2004;25(21):1940-1965.
- Penzkofer H, Wintersperger B, Smekal A, et al.** Qualitative and quantitative determination of regional myocardial perfusion with magnetic resonance tomography. *Radiologe* 1997;37(5):372-377.
- Pfafferoth C & Volger E.** Significance of blood viscosity for microcirculation. *Dtsch Med Wochenschr* 1983;108(48):1845-1851.

Pokrovsky SN, Sussekov A, Afanasieva OI, et al. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): preliminary clinical data. *Chem Phys Lipids* 1994;67-68:323-330.

Purcell EM, Torrey HC & Pound RV. Resonance absorption by nuclear magnetic moments in a solid. *Phys Rev* 1946;69:37-38.

Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. *Arteriosclerosis* 1989;9(5):579-592.

Resch KL, Ernst E, Matrai A, Buhl M, Schlosser P, Paulsen HF. Can rheologic variables be of prognostic relevance in arteriosclerotic diseases? *Angiology* 1991;42(12):963-970.

Richter WO, Jacob BG, Ritter MM; Suhler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. *Metabolism* 1993;42(7):888-894.

Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung (Richtlinie Methoden vertragsärztliche Versorgung). *Bundesanzeiger* 2007; Nr. 79, S.4 362.

Ridker PM, Hennekens CH & Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. *JAMA* 1993;270(18):2195-2199.

Ritter MM, Sühler K, Richter WO, Schwandt P. Short- and long-term effects of LDL-apheresis on lipoprotein(a) serum levels. *Clin Chim Acta* 1990;195(1-2):9-15.

Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993;362(6423):801-809.

Rubanyi GM, Romero JC & Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. *Am J Physiol* 1986;250(6Pt 2):H1145-H1149.

Sabbah HN, Marzilli M & Stein PD. The relative role of subendocardium and subepicardium in left ventricular mechanics. *American Journal of Physiology* 1981;240:H920-926.

Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibrinogen and has a serine proteinase activity capable of cleaving it. *EMBO J* 1989;8(13):4035-4040.

Sandholzer CD, Hallmann M, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on Lp(a) lipoprotein concentration in 7 ethnic groups. *Hum Genet* 1991;86(6):607-614.

Schachinger V, Halle M, Minners J, Berg A, Zeiher AM. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation *J Am Coll Cardiol* 1997;30(4):927-934.

Schelhase T & Rübenach P. Die Todesursachenstatistik – Methodik und Ergebnisse 2004. In: Statistisches Bundesamt, Wirtschaft und Statistik, 6/2006.

Schmitt M, Mohrs OK, Petersen SE, et al. Evaluation of myocardial perfusion reserve in patients with CAD using contrast-enhanced MRI: a comparison between semiquantitative and quantitative methods. *Rofo* 2002;174(2):187-195.

Schuff-Werner P, Schütz E, Seyde WC, et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). *Eur J Clin Invest* 1989;19(1):30-37.

Schwitzer J, Nanz D, Kneifel S, et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. *Circulation* 2001;103(18):2230-2235.

Sensky PR, Samani NJ, Reek C, Cherryman GR. Magnetic resonance perfusion imaging in patients with coronary artery disease: a qualitative approach. *Int J Cardiovasc Imaging* 2002;18(5):373-383.

Sing CF & Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. *Am J Hum Genet* 1985;37(2):268-285.

Song Y, Stampfer MJ & Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. *Ann Intern Med* 2004;141(2):137-147.

Stary, HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1994;89(5):2462-2478.

Steinhagen Thiessen E & Borchelt M. Morbidität, Medikation und Funktionalität im Alter. In: Mayer KU, Baltes PB (Hrsg). *Die Berliner Altersstudie (BASE)*, 1996. S. 151-183.

Straube R & Kingreen H. Lipoprotein(a) immunopheresis in the treatment of familial lipoprotein(a) hyperlipoproteinemia in a patient with coronary heart disease. *Ther Apher* 1998;2(3):243-245.

Suzuki M, Yamane M, Matsugane T, et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. *Artif Organs* 1996;20(4):296-302.

Sweetnam PM, Thomas HF, Yarnell JWG, et al. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell Studies. *Eur Heart J* 1996;17(12):1814-1820.

Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependend vasodilatation in hypercholesterolemic humans. *Circulation* 1997;95(1):76-82.

Tasaki H, Yamashita K, Saito Y, et al. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. *Ther Apher Dial* 2006;10(1):32-41.

Taylor AJ, Al-Saadi N, Abdel-Aty H, et al. Elective percutaneous coronary intervention immediately impairs resting microvascular perfusion assessed by Cardiac magnetic resonance imaging. *Am Heart J* 2006;151(4):891.e1-7.

Thefeld W. Verbreitung der Herz-Kreislauf-Risikofaktoren Hypercholesterinämie, Übergewicht, Hypertonie und Rauchen in der Bevölkerung. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz* 2000;43:415-423.

The pooling project research group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. *J Chronic Dis* 1978;31(4):201-306.

Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 2005;353(1):46-57.

Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S. Influence of plasma lipoprotein(a) levels on coronary vasomotor response to acetylcholine. *J Am Coll Cardiol* 1995; 26(5):1242-1250.

Ullrich H, Lackner K & Schmitz G. Lipoprotein(a)-apheresis in severe coronary heart disease: an immunoadsorption method. *Artif Org* 1998;22(2):135-139.

- Utermann G, Pruin N & Steinmetz A.** Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. *Clin Genet* 1979;15(1):63-72.
- Utermann G, Menzel HJ, Kraft HG, Duba HC, Kremmler HG, Seitz C.** Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. *J Clin Invest* 1987;80(2):458-465.
- Utermann G.** The mysteries of lipoprotein(a). *Science* 1989;246(4932):904-910.
- Utz W, Niendorf T, Wassmuth R, Messroghli D, Dietz R, Schulz-Menger J.** Contrast-dose relation in first-pass myocardial MR perfusion imaging. *J Magn Reson Imaging* 2007;25(6):1131-1135.
- Vane JR, Änggård EE & Botting RM.** Regulatory functions of the vascular endothelium. *N Engl J Med* 1990;323(1):27-36.
- Vita JA, Treasure CB, Nabel EG, et al.** Coronary vasomotor response to acetylcholin relates to risk factors for coronary artery disease. *Circulation* 1990;81(2):491-497.
- Weinmann HJ, Brasch RC, Press WR, Wesby GE.** Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. *AJR Am J Roentgenol* 1984;142(3):619-624.
- Weisgraber KH, Rall SC Jr & Mahley RW.** Human E apoprotein heterogeneity. Cysteine arginine interchanges in the amino acid sequence of the ApoE isoforms. *J Biol Chem* 1981; 256(17):9077-9083.
- World Health Organisation Technical Report Series.** The classification of atherosclerotic lesions. Report from a study group 1958; Series No. 143,pp 1-20.
- Wild SH, Fortmann SP & Marcovina SM.** A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Thromb Vasc Biol* 1997;17(2):239-245.
- Wilhelmsen L, Svärdsudd K, Korsan-Bengtzen K, et al.** Fibrinogen as a risk factor for stroke and myocardial infarction. *N Engl J Med* 1984;311(8):510-515.
- Wu HD, Berglund L, Dimayuga C, et al.** High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. *J Am Coll Cardiol* 2004;43(10):1828-1833.
- Young SG.** Recent progress in understanding apolipoprotein B. *Circulation* 1990;82(5):1574-1594.

Zaacks SM, Ali A, Parrillo JE, Barron JT. How well does radionuclide dipyridamole stress testing detect three-vessel coronary artery disease and ischemia in the region supplied by the most stenotic vessel? *Clin Nucl Med* 1999;24(1):35-41.

Zannis VI, Breslow JL, Utermann G, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. *J Lipid Res* 1982;23(6):911-914.

Zeiber AM, Drexler H, Saubier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia and hypertension. *J Clin Invest* 1993;92(2):652-662.

Zeiber AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. *Circulation* 1995;91(9):2345-2352.